ANAPTYSBIO INC
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
ANAB$48.38+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands)
| Common Stock · AdditionalPaid-in Capital · Accumulated Other Comprehensive Gain (Loss) · AccumulatedDeficit · TotalStockholders’Equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||
| Balance, January 1, 2022 | 27,647 | $28 | $678,575 | $(422) | $(321,753) | $356,428 | |||
| Issuance of common stock from exercises of options and employee stock purchase plan | 866 | 1 | 11,866 | — | — | 11,867 | |||
| Stock-based compensation | — | — | 27,356 | — | — | 27,356 | |||
| Comprehensive loss | — | — | — | (4,824) | — | (4,824) | |||
| Net loss | — | — | — | — | (128,724) | (128,724) | |||
| Balance, December 31, 2022 | 28,513 | 29 | 717,797 | (5,246) | (450,477) | 262,103 | |||
| Issuance of common stock from exercises of options and employee stock purchase plan | 139 | — | 2,421 | — | — | 2,421 | |||
| Issuance of common stock upon vesting of restricted stock units | 69 | — | — | — | — | — | |||
| Repurchases and retirements of common stock | (2,124) | (2) | (50,454) | (50,456) | |||||
| Stock-based compensation | — | — | 33,205 | — | — | 33,205 | |||
| Comprehensive income | — | — | — | 4,449 | — | 4,449 | |||
| Net loss | — | — | — | — | (163,619) | (163,619) | |||
| Balance, December 31, 2023 | 26,597 | 27 | 702,969 | (797) | (614,096) | 88,103 | |||
| Issuance of common stock from exercises of options and employee stock purchase plan | 364 | — | 6,473 | — | — | 6,473 | |||
| Issuance of common stock upon vesting of restricted stock units | 1,108 | — | — | — | — | — | |||
| Net share settlement of restricted stock units | (347) | — | (7,504) | — | (7,504) | ||||
| Issuance of common stock, net of $6,516 of transaction costs | 2,751 | 3 | 93,874 | — | — | 93,877 | |||
| Stock-based compensation | — | — | 34,048 | — | — | 34,048 | |||
| Comprehensive income | — | — | — | 1,102 | — | 1,102 | |||
| Net loss | — | — | — | — | (145,231) | (145,231) | |||
| Balance, December 31, 2024 | 30,473 | $30 | $829,860 | $305 | $(759,327) | $70,868 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.